Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

By J. S. San Miguel, R. Schlag, Nuriet K. Khuageva, M. Dimopoulos, O. Shpilberg, M. Kropff, I. Špička, M. Petrucci, A. Palumbo, O. Samoilova and 11 more. New England Journal of Medicine, 2008

1,733 citations recorded by the source corpus.

Subfields: Ecology, Evolution, Behavior and Systematics

View Paper: https://www.semanticscholar.org/paper/a5e1dee0af796f3ba3bf45e30ced8f32871e02d2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. T. Hideshima
2. P. Richardson
3. S. Rajkumar
4. C. Mitsiades
5. I. Ghobrial
6. S. Jagannath
7. K. Anderson
8. Thomas J. Smith

Citations in the corpus

• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011, background): “Studies are being conducted worldwide, including an increasing number of multi-center, international trials.(2,3) It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results.”
• Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. (2010, neutral): “Fatigue 33 (15) 20 (9) 0·08 Neuropathy 5 ( 2 ) 4 (2) 0·1”
• Environment-mediated drug resistance: a major contributor to minimal residual disease (2009, background): “aspx?CdrID=42487">prednisone chemotherapy for initial treatment of patients who are ineligible for high-dose melphalan therap”